HRP20000722B1 - Postupak za sintezu cox-2 inhibitora - Google Patents

Postupak za sintezu cox-2 inhibitora

Info

Publication number
HRP20000722B1
HRP20000722B1 HR20000722A HRP20000722A HRP20000722B1 HR P20000722 B1 HRP20000722 B1 HR P20000722B1 HR 20000722 A HR20000722 A HR 20000722A HR P20000722 A HRP20000722 A HR P20000722A HR P20000722 B1 HRP20000722 B1 HR P20000722B1
Authority
HR
Croatia
Prior art keywords
6alkyl
alkyl
aryl
compound
formula
Prior art date
Application number
HR20000722A
Other languages
English (en)
Croatian (hr)
Inventor
Edward Corley G.
Ian Davies W.
Robert Larsen D.
Philip Pye J.
Rossen Kai
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of HRP20000722A2 publication Critical patent/HRP20000722A2/hr
Publication of HRP20000722B1 publication Critical patent/HRP20000722B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20000722A 1998-04-24 1999-04-20 Postupak za sintezu cox-2 inhibitora HRP20000722B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15
PCT/US1999/008645 WO1999055830A2 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Publications (2)

Publication Number Publication Date
HRP20000722A2 HRP20000722A2 (en) 2001-06-30
HRP20000722B1 true HRP20000722B1 (hr) 2009-07-31

Family

ID=26767964

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000722A HRP20000722B1 (hr) 1998-04-24 1999-04-20 Postupak za sintezu cox-2 inhibitora

Country Status (27)

Country Link
US (2) US6040319A (cs)
EP (1) EP1071745B1 (cs)
JP (2) JP3325264B2 (cs)
KR (1) KR100414998B1 (cs)
CN (1) CN1178658C (cs)
AR (1) AR015279A1 (cs)
AT (1) ATE272613T1 (cs)
AU (1) AU759469B2 (cs)
BR (2) BR9909844B1 (cs)
CA (1) CA2329193C (cs)
CZ (1) CZ292515B6 (cs)
DE (1) DE69919151T2 (cs)
DK (1) DK1071745T3 (cs)
EA (1) EA002975B1 (cs)
ES (1) ES2226378T3 (cs)
HR (1) HRP20000722B1 (cs)
HU (1) HU227627B1 (cs)
IL (2) IL139127A0 (cs)
NZ (1) NZ507597A (cs)
PL (1) PL193248B1 (cs)
PT (1) PT1071745E (cs)
RS (1) RS49945B (cs)
SI (1) SI1071745T1 (cs)
SK (1) SK284805B6 (cs)
TW (1) TW474934B (cs)
UA (1) UA57143C2 (cs)
WO (1) WO1999055830A2 (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2359958C (en) * 1999-01-14 2006-04-04 Lonza Ag Process for preparing 1-(6-methylpyridin-3yl)-2-[(4-methylsulfonyl)phenyl]ethanone
KR100446324B1 (ko) 1999-01-14 2004-08-30 론자 아게 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
ATE320809T1 (de) 1999-11-29 2006-04-15 Merck Frosst Canada Inc Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl
ES2236007T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
WO2006137839A2 (en) 2004-08-24 2006-12-28 Merck & Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
ES2496465T3 (es) 2009-02-27 2014-09-19 Cadila Healthcare Limited Un procedimiento para la preparación de Etoricoxib
WO2011158250A1 (en) 2010-06-16 2011-12-22 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
CA2817939A1 (en) 2010-11-15 2012-05-24 Virdev Intermediates Pvt. Ltd. A process for cyclooxygenase-2 selective inhibitor
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
SI2714676T1 (sl) 2011-05-27 2019-06-28 Farma Grs, D.O.O. Postopek za pripravo polimorfne oblike I etorikoksiba
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
EP2831045A2 (en) 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
HUE033525T2 (en) 2012-08-27 2017-12-28 Cadila Healthcare Ltd Pharmaceuticals containing Etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
ATE249437T1 (de) * 1996-07-18 2003-09-15 Merck Frosst Canada Inc Substituierte pyridine als selektive cyclooxygenase inhibitoren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
CA2329193C (en) 2007-01-23
DE69919151T2 (de) 2005-07-28
EA200001102A1 (ru) 2001-04-23
AU759469B2 (en) 2003-04-17
JP2003040852A (ja) 2003-02-13
SK15892000A3 (sk) 2001-07-10
US6252116B1 (en) 2001-06-26
WO1999055830A3 (en) 1999-12-29
BR9909844A (pt) 2001-04-03
AU3655799A (en) 1999-11-16
HK1031399A1 (en) 2001-06-15
KR100414998B1 (ko) 2004-01-13
CN1306425A (zh) 2001-08-01
EA002975B1 (ru) 2002-12-26
TW474934B (en) 2002-02-01
ES2226378T3 (es) 2005-03-16
SI1071745T1 (en) 2004-10-31
CZ292515B6 (cs) 2003-10-15
EP1071745B1 (en) 2004-08-04
JP3834263B2 (ja) 2006-10-18
BRPI9917739B1 (pt) 2016-05-03
JP2002513035A (ja) 2002-05-08
IL139127A0 (en) 2001-11-25
DE69919151D1 (de) 2004-09-09
WO1999055830A2 (en) 1999-11-04
SK284805B6 (sk) 2005-11-03
BRPI9917739B8 (pt) 2021-05-25
HU227627B1 (en) 2011-10-28
HUP0101407A3 (en) 2002-12-28
CA2329193A1 (en) 1999-11-04
YU64100A (sh) 2002-11-15
EP1071745A2 (en) 2001-01-31
BR9909844B1 (pt) 2010-10-19
NZ507597A (en) 2004-02-27
JP3325264B2 (ja) 2002-09-17
CN1178658C (zh) 2004-12-08
ATE272613T1 (de) 2004-08-15
HRP20000722A2 (en) 2001-06-30
KR20010042941A (ko) 2001-05-25
UA57143C2 (uk) 2003-06-16
PT1071745E (pt) 2004-11-30
PL193248B1 (pl) 2007-01-31
EP1071745A4 (en) 2002-05-15
US6040319A (en) 2000-03-21
IL139127A (en) 2006-07-05
HUP0101407A2 (hu) 2001-09-28
RS49945B (sr) 2008-09-29
DK1071745T3 (da) 2004-11-29
CZ20003940A3 (en) 2001-06-13
AR015279A1 (es) 2001-04-18
PL344108A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
HRP20000722B1 (hr) Postupak za sintezu cox-2 inhibitora
DE69726309D1 (de) Zuckerderivate, geliermittel, geliermittelzubereitungen, verfahren zu ihrer herstellung und gelzubereitungen
DE59603876D1 (de) Verfahren zur herstellung von chinazolinderivaten
UA41365C2 (uk) Похідні азоліламіну та фунгіцидний засіб на їх основі
NO177300C (no) Analogifremgangsmåte for fremstilling av et kinolinderivat og mellomprodukter
AU6822798A (en) Cycloalkylalkanecarboxamides and the production and use thereof
MX9701949A (es) Derivados de distamicina substituidos con bis-(2-haloetil) aminofenilo como agentes antitumorales y antivirales.
HRP20000878B1 (hr) Kemijska sinteza derivata morfolina
RS49829B (sr) Postupak i intermedijeri za proizvodnju piridin-2,3-dikarboksilat jedinjenja
DE69632919D1 (de) Verfahren zur herstellung von 2-chlor-5-chloromethyl-thiazol
DK0945430T3 (da) N-phenylacetoacetamider og fremgangsmåde til fremstilling deraf
AU5608090A (en) Amines
ATE115567T1 (de) Verfahren zur herstellung von halogensulfonyl- substituierten pyridinen.
KR830005104A (ko) 신규 벤젠아민 및 동물질을 함유하는 조성물의 제조방법
YU74501A (sh) Sinteza 3-amino-3-aril propionata
NO20000344D0 (no) Fremgangsmåte for fremstilling av 1,3-diaza-spiro (4,4) non-1- en-on-derivater og 1-cyano-1-acylaminsyklopentan-intermediater
TW351713B (en) A method for preparing 3-amino substituted crotonates
HK1038698A1 (zh) 合成有效制备三环化合物的中间体
ATE130295T1 (de) 4(5)-imidazole fähig zur inhibierung von aromatase.
ATE263766T1 (de) Verfahren zur synthese von carbapenem- zwischenprodukten
DK0728743T3 (da) (3-Amino)-tetrahydrocarbazolpropansyreestere
ATE244701T1 (de) Verfahren zur herstellung von arylsulfenylhalogeniden
YU45722B (sh) Postupak za dobijanje n-acil-4-ili n-acil-2-hidroksi fenil amina
YU78693A (sh) Postupak za dobijanje novih n-fenil supstituisanih amida 2,2-dimetilpropanske kiseline
DE69303577D1 (de) Verfahren zur Halognierung von Aromatischen Verbindungen

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20180412

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20190420